{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:47:03Z","timestamp":1793119623115,"version":"4.5.0"},"reference-count":196,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,2]],"date-time":"2017-06-02T00:00:00Z","timestamp":1496361600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.eururo.2017.06.002","type":"journal-article","created":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T21:01:40Z","timestamp":1498338100000},"page":"178-211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":391,"title":["Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017"],"prefix":"10.1016","volume":"73","author":[{"given":"Silke","family":"Gillessen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhardt","family":"Attard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz M.","family":"Beer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himisha","family":"Beltran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Bristow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Carver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Ha","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gedske","family":"Daugaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian D.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"de Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo","family":"Borges dos Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles G.","family":"Drake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ros","family":"Eeles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Efstathiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Fanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Frydenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gleave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Halabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Heidenreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celestia S.","family":"Higano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Kantoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pirkko-Liisa","family":"Kellokumpu-Lehtinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja B.","family":"Khauli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gero","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Logothetis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Maluf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia K.","family":"Morgans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Mottet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vedang","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piet","family":"Ost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwar R.","family":"Padhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin C.","family":"Pritchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mack","family":"Roach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Scher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avishay","family":"Sella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Soule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cora N.","family":"Sternberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyoshi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Sydes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Tannock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Tombal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Valdagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wiegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelius","family":"Omlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2017.06.002_bib0985","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/annonc\/mdv257","article-title":"Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015","volume":"26","author":"Gillessen","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2017.06.002_bib0990","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2013.12.002","article-title":"Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies","volume":"67","author":"Diamond","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.eururo.2017.06.002_bib0995","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1001\/jamaoncol.2015.4350","article-title":"Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE trial","volume":"2","author":"James","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1000","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/bju.12469","article-title":"Can we improve the definition of high-risk, hormone naive, non-metastatic prostate cancer?","volume":"113","author":"Tombal","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2017.06.002_bib1005","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"71","author":"Mottet","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1010","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3322\/caac.21391","article-title":"Prostate cancer\u2014major changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Buyyounouski","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.eururo.2017.06.002_bib1015","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/PAS.0000000000000820","article-title":"Contemporary Gleason Grading of Prostatic Carcinoma: an update with discussion on practical issues to implement the 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma","volume":"41","author":"Epstein","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1020","series-title":"WHO Classification of Tumours of the Urinary System and Male Genital Organs","author":"Moch","year":"2016"},{"key":"10.1016\/j.eururo.2017.06.002_bib1025","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/bju.12342","article-title":"Prognosis of patients with pelvic lymph node (LN) metastasis after radical prostatectomy: value of extranodal extension and size of the largest LN metastasis","volume":"114","author":"Passoni","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2017.06.002_bib1030","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2011.10.044","article-title":"Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores","volume":"61","author":"Briganti","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1035","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1089\/end.2013.0571","article-title":"External validation of the European association of urology recommendations for pelvic lymph node dissection in patients treated with robot-assisted radical prostatectomy","volume":"28","author":"Dell\u2019Oglio","year":"2014","journal-title":"J Endourol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1040","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1159\/000354323","article-title":"Validation of nomograms predicting lymph node involvement in patients with prostate cancer undergoing extended pelvic lymph node dissection","volume":"92","author":"Hinev","year":"2014","journal-title":"Urol Int"},{"key":"10.1016\/j.eururo.2017.06.002_bib1045","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.urology.2014.07.059","article-title":"NADiA ProsVue prostate-specific antigen slope, CAPRA-S, and prostate cancer-specific survival after radical prostatectomy","volume":"84","author":"Moul","year":"2014","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2017.06.002_bib1050","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(12)61253-7","article-title":"Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)","volume":"380","author":"Bolla","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2017.06.002_bib1055","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2014.03.011","article-title":"Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96\u201302\/AUO AP 09\/95 Trial","volume":"66","author":"Wiegel","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1060","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.juro.2008.11.032","article-title":"Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial","volume":"181","author":"Thompson","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1065","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/jncimonographs\/lgs039","article-title":"Overview of randomized controlled treatment trials for clinically localized prostate cancer: implications for active surveillance and the United States preventative task force report on screening?","volume":"2012","author":"Roach","year":"2012","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1016\/j.eururo.2017.06.002_bib1070","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.eururo.2017.01.039","article-title":"Adjuvant and salvage radiotherapy after radical prostatectomy in prostate cancer patients","volume":"72","author":"Gandaglia","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1075","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.eururo.2014.05.011","article-title":"More extensive pelvic lymph node dissection improves survival in patients with node-positive prostate cancer","volume":"67","author":"Abdollah","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1080","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.eururo.2012.04.056","article-title":"Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis","volume":"62","author":"Briganti","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1085","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer","volume":"71","author":"Cornford","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1090","unstructured":"National Comprehensive Cancer Network. Prostate Cancer. 2017. https:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp."},{"key":"10.1016\/j.eururo.2017.06.002_bib1095","doi-asserted-by":"crossref","unstructured":"Tendulkar RD, Agrawal S, Gao T, et al. Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy. J Clin Oncol. In press. http:\/\/dx.doi.org\/10.1200\/JCO.2016.67.9647.","DOI":"10.1200\/JCO.2016.67.9647"},{"key":"10.1016\/j.eururo.2017.06.002_bib1100","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.juro.2016.08.106","article-title":"Very early salvage radiotherapy improves distant metastasis-free survival","volume":"197","author":"Abugharib","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1105","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(16)00111-X","article-title":"Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial","volume":"17","author":"Carrie","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1110","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1607529","article-title":"Radiation with or without antiandrogen therapy in recurrent prostate cancer","volume":"376","author":"Shipley","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2017.06.002_bib1115","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.juro.2016.09.079","article-title":"Early postoperative radiotherapy is associated with worse functional outcomes in patients with prostate cancer","volume":"197","author":"Zaffuto","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1120","doi-asserted-by":"crossref","unstructured":"Shaikh MP, Alite F, Wu MJ, Solanki AA, Harkenrider MM. Adjuvant radiotherapy versus wait-and-see strategy for pathologic T3 or margin-positive prostate cancer: a meta-analysis. Am J Clin Oncol. In press. http:\/\/dx.doi.org\/10.1097\/COC.0000000000000358.","DOI":"10.1097\/COC.0000000000000358"},{"key":"10.1016\/j.eururo.2017.06.002_bib1125","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(10)70223-0","article-title":"External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study","volume":"11","author":"Bolla","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1130","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(02)09408-4","article-title":"Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial","volume":"360","author":"Bolla","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2017.06.002_bib1135","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1200\/JCO.2007.13.9881","article-title":"Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610","volume":"26","author":"Roach","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1140","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1200\/JCO.1997.15.3.1013","article-title":"Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31","volume":"15","author":"Pilepich","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1145","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S0090-4295(99)80053-3","article-title":"Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group","volume":"45","author":"Pilepich","year":"1995","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2017.06.002_bib1150","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1155","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrurol.2016.175","article-title":"Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations","volume":"14","author":"Tosoian","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1160","doi-asserted-by":"crossref","first-page":"8491","DOI":"10.18632\/oncotarget.3455","article-title":"The biology and treatment of oligometastatic cancer","volume":"6","author":"Reyes","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.eururo.2017.06.002_bib1165","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.eururo.2014.09.004","article-title":"Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature","volume":"67","author":"Ost","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1170","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.juro.2015.04.103","article-title":"Management of node only recurrence after primary local treatment for prostate cancer: a systematic review of the literature","volume":"194","author":"Ploussard","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1175","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1056\/NEJM198411153112004","article-title":"Leuprolide versus diethylstilbestrol for metastatic prostate cancer","volume":"311","author":"Leuprolide Study","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2017.06.002_bib1180","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1200\/JCO.2014.55.1192","article-title":"Long-term follow-up of a large active surveillance cohort of patients with prostate cancer","volume":"33","author":"Klotz","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1185","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ejca.2011.10.015","article-title":"A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial","volume":"48","author":"Fizazi","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2017.06.002_bib1190","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S1470-2045(15)00011-X","article-title":"Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial","volume":"16","author":"Fizazi","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1195","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2017.06.002_bib1200","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S1470-2045(15)00489-1","article-title":"Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data","volume":"17","author":"Vale","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1205","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0140-6736(00)02163-2","article-title":"Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists\u2019 Collaborative Group","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2017.06.002_bib1210","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.eururo.2014.09.032","article-title":"Survival with newly diagnosed metastatic prostate cancer in the \u201cdocetaxel era\u201d: data from 917 patients in the control arm of the STAMPEDE Trial (MRC PR08, CRUK\/06\/019)","volume":"67","author":"James","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1215","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","article-title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial","volume":"14","author":"Gravis","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1220","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.eururo.2014.09.022","article-title":"Prognostic factors for survival in noncastrate metastatic prostate cancer: validation of the glass model and development of a novel simplified prognostic model","volume":"68","author":"Gravis","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1225","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2017.06.002_bib1230","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.eururo.2015.11.005","article-title":"Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial","volume":"70","author":"Gravis","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1235","doi-asserted-by":"crossref","first-page":"18217","DOI":"10.1038\/srep18217","article-title":"The significance of G-CSF expression and myeloid-derived suppressor cells in the chemoresistance of uterine cervical cancer","volume":"5","author":"Kawano","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.eururo.2017.06.002_bib1240","doi-asserted-by":"crossref","first-page":"e27690","DOI":"10.1371\/journal.pone.0027690","article-title":"Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism","volume":"6","author":"Waight","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.eururo.2017.06.002_bib1245","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/ncb3355","article-title":"Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation","volume":"18","author":"Welte","year":"2016","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1250","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2015.01.022","article-title":"Locoregional symptoms in patients with de novo metastatic prostate cancer: morbidity, management, and disease outcome","volume":"33","author":"Patrikidou","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1255","doi-asserted-by":"crossref","first-page":"E250","DOI":"10.1111\/bju.12169","article-title":"Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer","volume":"112","author":"Won","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2017.06.002_bib1260","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.eururo.2013.11.012","article-title":"Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study","volume":"65","author":"Culp","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1265","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.2016.67.4788","article-title":"Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer","volume":"34","author":"Rusthoven","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1270","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.eururo.2016.04.031","article-title":"The Impact of local treatment on overall survival in patients with metastatic prostate cancer on diagnosis: a national cancer data base analysis","volume":"72","author":"Loppenberg","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1275","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.eururo.2009.12.034","article-title":"Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer","volume":"57","author":"Engel","year":"2010","journal-title":"Eur Urol"},{"issue":"7","key":"10.1016\/j.eururo.2017.06.002_bib1280","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv119","article-title":"Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer","volume":"107","author":"Lin","year":"2015","journal-title":"J Natl Cancer Inst."},{"key":"10.1016\/j.eururo.2017.06.002_bib1285","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1158\/2159-8290.CD-13-0172","article-title":"Androgen receptor signaling regulates DNA repair in prostate cancers","volume":"3","author":"Polkinghorn","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eururo.2017.06.002_bib1290","doi-asserted-by":"crossref","first-page":"6259","DOI":"10.1073\/pnas.1600420113","article-title":"Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression","volume":"113","author":"Komura","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.eururo.2017.06.002_bib1295","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrurol.2016.221","article-title":"Androgen synthesis in prostate cancer: do all roads lead to Rome?","volume":"14","author":"Stuchbery","year":"2017","journal-title":"Nat Rev Urol."},{"key":"10.1016\/j.eururo.2017.06.002_bib1300","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2017.06.002_bib1305","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2017.06.002_bib1310","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/S1470-2045(15)00135-7","article-title":"Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial","volume":"16","author":"Badwe","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1315","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2017.06.002_bib1320","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2017.06.002_bib1325","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2017.06.002_bib1330","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2017.06.002_bib1335","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2017.06.002_bib1340","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2017.06.002_bib1345","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2017.06.002_bib1350","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2017.06.002_bib1355","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2017.06.002_bib1360","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/annonc\/mdw156","article-title":"Anti-tumour activity of platinum compounds in advanced prostate cancer-a systematic literature review","volume":"27","author":"Hager","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1365","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrurol.2014.345","article-title":"Switching and withdrawing hormonal agents for castration-resistant prostate cancer","volume":"12","author":"Lorente","year":"2015","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1370","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1038\/bjc.2014.531","article-title":"Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone","volume":"111","author":"Lorente","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2017.06.002_bib1375","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1470-2045(12)70537-5","article-title":"2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial","volume":"14","author":"Kellokumpu-Lehtinen","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1380","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.eururo.2013.10.055","article-title":"Visceral disease in castration-resistant prostate cancer","volume":"65","author":"Pezaro","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1385","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1158\/1078-0432.CCR-13-3309","article-title":"Aggressive variants of castration-resistant prostate cancer","volume":"20","author":"Beltran","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2017.06.002_bib1390","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.eururo.2017.06.002_bib1395","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1158\/1078-0432.CCR-12-3791","article-title":"Platinum-based chemotherapy for variant castrate-resistant prostate cancer","volume":"19","author":"Aparicio","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2017.06.002_bib1400","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1093\/annonc\/mdx044","article-title":"An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223","volume":"28","author":"Sartor","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1405","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/pcan.2017.6","article-title":"Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases-analysis of an international multicenter database","volume":"20","author":"Keizman","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2017.06.002_bib1410","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.lungcan.2017.02.007","article-title":"SBRT for oligoprogressive oncogene addicted NSCLC","volume":"106","author":"Basler","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.eururo.2017.06.002_bib1415","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/PAS.0000000000000208","article-title":"Proposed morphologic classification of prostate cancer with neuroendocrine differentiation","volume":"38","author":"Epstein","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1420","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.eururo.2016.05.033","article-title":"METastasis Reporting and Data System for Prostate Cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate cancer","volume":"71","author":"Padhani","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1425","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1093\/annonc\/mdv360","article-title":"Reply to the letter to the editor \u2018management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015\u2019 by Gillessen et al","volume":"26","author":"Gillessen","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1430","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/nrurol.2015.242","article-title":"Imaging and evaluation of patients with high-risk prostate cancer","volume":"12","author":"Bjurlin","year":"2015","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1435","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s00345-016-1803-9","article-title":"Non-metastatic castrate-resistant prostate cancer: a call for improved guidance on clinical management","volume":"34","author":"Rozet","year":"2016","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1440","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.crad.2007.05.022","article-title":"The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis","volume":"63","author":"Hovels","year":"2008","journal-title":"Clin Radiol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1445","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.eururo.2012.02.020","article-title":"Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer?","volume":"62","author":"Lecouvet","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1450","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/0284186X.2015.1027411","article-title":"Prospective evaluation of planar bone scintigraphy, SPECT, SPECT\/CT, 18F-NaF PET\/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial","volume":"55","author":"Jambor","year":"2016","journal-title":"Acta Oncol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1455","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s00256-014-1903-9","article-title":"Comparison of choline-PET\/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis","volume":"43","author":"Shen","year":"2014","journal-title":"Skeletal Radiol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1460","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.eururo.2017.03.042","article-title":"Diagnostic performance of magnetic resonance imaging for the detection of bone metastasis in prostate cancer: a systematic review and meta-analysis","volume":"73","author":"Woo","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1465","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.2967\/jnumed.115.162610","article-title":"Prospective comparison of 99mTc-MDP scintigraphy, combined 18F-NaF and 18F-FDG PET\/CT, and whole-body MRI in patients with breast and prostate cancer","volume":"56","author":"Minamimoto","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2017.06.002_bib1470","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s00259-016-3490-6","article-title":"Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET\/CT","volume":"44","author":"Schwenck","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2017.06.002_bib1475","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.juro.2016.09.117","article-title":"Multisite experience of the safety, detection rate and diagnostic performance of fluciclovine (18F) positron emission tomography\/computerized tomography imaging in the staging of biochemically recurrent prostate cancer","volume":"197","author":"Bach-Gansmo","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1480","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s00259-016-3329-1","article-title":"(18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET\/CT in prostate cancer relapse: results of a prospective trial","volume":"43","author":"Nanni","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2017.06.002_bib1485","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.juro.2012.03.008","article-title":"Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer","volume":"188","author":"Yu","year":"2012","journal-title":"J Urolo"},{"key":"10.1016\/j.eururo.2017.06.002_bib1490","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/RLU.0b013e3182867f3c","article-title":"Choline PET or PET\/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis","volume":"38","author":"Evangelista","year":"2013","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.eururo.2017.06.002_bib1495","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1007\/s00259-015-3123-5","article-title":"Prognostic value of metabolic parameters and clinical impact of (1)(8)F-fluorocholine PET\/CT in biochemical recurrent prostate cancer","volume":"42","author":"Colombie","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2017.06.002_bib1500","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00259-015-3015-8","article-title":"[(1)(1)C]Choline PET\/CT predicts survival in hormone-naive prostate cancer patients with biochemical failure after radical prostatectomy","volume":"42","author":"Giovacchini","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2017.06.002_bib1505","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1007\/s00259-016-3366-9","article-title":"Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with (68)Ga-PSMA-HBED-CC than with (18)F-Fluoroethylcholine PET\/CT","volume":"43","author":"Pfister","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2017.06.002_bib1510","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.2967\/jnumed.115.160382","article-title":"Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET\/CT in prostate cancer patients who have rising PSA After curative treatment and are being considered for targeted therapy","volume":"56","author":"Morigi","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2017.06.002_bib1515","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00259-014-2949-6","article-title":"The diagnostic value of PET\/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer","volume":"42","author":"Afshar-Oromieh","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2017.06.002_bib1520","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2967\/jnumed.115.154153","article-title":"Evaluation of hybrid (6)(8)Ga-PSMA Ligand PET\/CT in 248 patients with biochemical recurrence after radical prostatectomy","volume":"56","author":"Eiber","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2017.06.002_bib1525","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1530","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2014.55.3875","article-title":"Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results","volume":"33","author":"Morris","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1535","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/pcan.2016.71","article-title":"Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL","volume":"20","author":"Bryce","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2017.06.002_bib1540","doi-asserted-by":"crossref","first-page":"9578","DOI":"10.1073\/pnas.1106383108","article-title":"Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen","volume":"108","author":"Evans","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.eururo.2017.06.002_bib1545","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.2217\/fon-2016-0312","article-title":"Targeted PET imaging for prostate-specific membrane antigen in prostate cancer","volume":"12","author":"Hope","year":"2016","journal-title":"Future Oncol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1550","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2967\/jnumed.116.181800","article-title":"68Ga-PSMA-11 PET imaging of response to androgen receptor inhibition: first human experience","volume":"58","author":"Hope","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2017.06.002_bib1555","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0090-4295(96)00184-7","article-title":"Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy","volume":"48","author":"Wright","year":"1996","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2017.06.002_bib1560","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1158\/2159-8290.CD-12-0222","article-title":"Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer","volume":"2","author":"Miyamoto","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eururo.2017.06.002_bib1565","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13550-015-0145-8","article-title":"Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy","volume":"5","author":"Meller","year":"2015","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.eururo.2017.06.002_bib1570","doi-asserted-by":"crossref","first-page":"81","DOI":"10.18383\/j.tom.2015.00169","article-title":"Uptake of 18F-DCFPyL in Paget's disease of bone, an important potential pitfall in clinical interpretation of PSMA PET studies","volume":"1","author":"Rowe","year":"2015","journal-title":"Tomography"},{"key":"10.1016\/j.eururo.2017.06.002_bib1575","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.cpet.2016.12.004","article-title":"Gallium-68 prostate-specific membrane antigen PET imaging","volume":"12","author":"Hofman","year":"2017","journal-title":"PET Clin"},{"key":"10.1016\/j.eururo.2017.06.002_bib1580","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1007\/s00259-015-3042-5","article-title":"(18)F-Fluorocholine PET\/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide","volume":"42","author":"De Giorgi","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2017.06.002_bib1585","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2017.06.002_bib1590","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1148\/radiol.2016160646","article-title":"Diffusion-weighted imaging as a treatment response biomarker for evaluating bone metastases in prostate cancer: a pilot study","volume":"283","author":"Perez-Lopez","year":"2017","journal-title":"Radiology"},{"key":"10.1016\/j.eururo.2017.06.002_bib1595","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2017.06.002_bib1600","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3816\/CGC.2002.n.016","article-title":"Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone","volume":"1","author":"Saad","year":"2002","journal-title":"Clin Prostate Cancer"},{"key":"10.1016\/j.eururo.2017.06.002_bib1605","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2017.06.002_bib1610","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2017.06.002_bib1615","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1200\/JCO.2013.51.6500","article-title":"Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance)","volume":"32","author":"Smith","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1620","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1001\/jamaoncol.2015.5570","article-title":"Clinical outcomes and survival following treatment of metastatic castrate-refractory prostate cancer with docetaxel alone or with strontium-89, zoledronic acid, or both: The TRAPEZE randomized clinical trial","volume":"2","author":"James","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1625","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdu519","article-title":"Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events","volume":"26","author":"Smith","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1630","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(14)70183-4","article-title":"Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial","volume":"15","author":"Sartor","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1635","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2016.19425","article-title":"Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial","volume":"317","author":"Himelstein","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2017.06.002_bib1640","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/sj.bdj.2015.680","article-title":"New cancer therapies and jaw necrosis","volume":"219","author":"Patel","year":"2015","journal-title":"Br Dent J"},{"key":"10.1016\/j.eururo.2017.06.002_bib1645","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1650","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.4045","article-title":"Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer","volume":"22","author":"Beltran","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.eururo.2017.06.002_bib1655","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/jamaoncol.2015.1313","article-title":"Whole-exome sequencing of metastatic cancer and biomarkers of treatment response","volume":"1","author":"Beltran","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1660","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-15-1259","article-title":"Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers","volume":"22","author":"Aparicio","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2017.06.002_bib1665","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ccell.2016.09.005","article-title":"N-Myc Induces an EZH2-mediated transcriptional program driving neuroendocrine prostate cancer","volume":"30","author":"Dardenne","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2017.06.002_bib1670","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-15-1263","article-title":"The master neural transcription factor BRN2 is an androgen receptor-suppressed driver of neuroendocrine differentiation in prostate cancer","volume":"7","author":"Bishop","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eururo.2017.06.002_bib1675","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.eururo.2016.04.028","article-title":"SRRM4 drives neuroendocrine transdifferentiation of prostate adenocarcinoma under androgen receptor pathway inhibition","volume":"71","author":"Li","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1680","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.aah4307","article-title":"SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer","volume":"355","author":"Mu","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.eururo.2017.06.002_bib1685","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.eururo.2017.06.002_bib1690","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2017.06.002_bib1695","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1126\/science.aah4199","article-title":"Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance","volume":"355","author":"Ku","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.eururo.2017.06.002_bib1700","doi-asserted-by":"crossref","first-page":"4988","DOI":"10.1038\/ncomms5988","article-title":"Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer","volume":"5","author":"Pritchard","year":"201425","journal-title":"Nat Commun."},{"key":"10.1016\/j.eururo.2017.06.002_bib1705","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1001\/jamaoncol.2016.0494","article-title":"Genomic Alterations in cell-free dna and enzalutamide resistance in castration-resistant prostate cancer","volume":"2","author":"Wyatt","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1710","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2017.06.002_bib1715","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1158\/1078-0432.CCR-16-1070","article-title":"Association of AR-V7 and prostate-specific antigen RNA levels in blood with efficacy of abiraterone acetate and enzalutamide treatment in men with prostate cancer","volume":"23","author":"Qu","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2017.06.002_bib1720","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.eururo.2016.08.012","article-title":"The detection of androgen receptor splice variant 7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients","volume":"71","author":"Del Re","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1725","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1001\/jamaoncol.2016.1828","article-title":"Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer","volume":"2","author":"Scher","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1730","doi-asserted-by":"crossref","first-page":"312re10","DOI":"10.1126\/scitranslmed.aac9511","article-title":"Plasma AR and abiraterone-resistant prostate cancer","volume":"7","author":"Romanel","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.eururo.2017.06.002_bib1735","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature11125","article-title":"The mutational landscape of lethal castration-resistant prostate cancer","volume":"487","author":"Grasso","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2017.06.002_bib1740","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.eururo.2016.08.037","article-title":"DNA repair in prostate cancer: biology and clinical implications","volume":"71","author":"Mateo","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1745","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.eururo.2015.11.022","article-title":"Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer","volume":"69","author":"Cheng","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1750","doi-asserted-by":"crossref","first-page":"5431","DOI":"10.1200\/JCO.2008.20.1228","article-title":"Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial","volume":"27","author":"Sternberg","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1755","first-page":"223","article-title":"Mismatch repair enzyme expression in primary and castrate resistant prostate cancer Asian","volume":"3","author":"Nghiem","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1760","doi-asserted-by":"crossref","first-page":"82504","DOI":"10.18632\/oncotarget.12697","article-title":"Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate","volume":"7","author":"Schweizer","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.eururo.2017.06.002_bib1765","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2017.06.002_bib1770","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/107327480701400111","article-title":"Cancer incidence among Korean-American immigrants in the United States and native Koreans in South Korea","volume":"14","author":"Lee","year":"2007","journal-title":"Cancer Control"},{"key":"10.1016\/j.eururo.2017.06.002_bib1775","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jama.2015.17703","article-title":"Familial risk and heritability of cancer among twins in Nordic countries","volume":"315","author":"Mucci","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2017.06.002_bib1780","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/jnci\/86.21.1600","article-title":"Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands","volume":"86","author":"Goldgar","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2017.06.002_bib1785","series-title":"Male Reproductive Cancers: Epidemiology, Pathology and Genetics","author":"Lange","year":"2010"},{"key":"10.1016\/j.eururo.2017.06.002_bib1790","first-page":"4056","article-title":"Evaluation of prostate cancer characteristics in four populations worldwide","volume":"15","author":"Zeigler-Johnson","year":"2008","journal-title":"Canadian J Urol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1795","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1086\/320114","article-title":"Segregation analyses of 1,476 population-based Australian families affected by prostate cancer","volume":"68","author":"Cui","year":"2001","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.eururo.2017.06.002_bib1800","doi-asserted-by":"crossref","first-page":"FSO87","DOI":"10.4155\/fso.15.87","article-title":"Germline genetic profiling in prostate cancer: latest developments and potential clinical applications","volume":"2","author":"Ahmed","year":"2016","journal-title":"Future Sci OA"},{"key":"10.1016\/j.eururo.2017.06.002_bib1805","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1086\/318181","article-title":"Variation in cancer risks, by mutation position, in BRCA2 mutation carriers","volume":"68","author":"Thompson","year":"2001","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.eururo.2017.06.002_bib1810","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1038\/bjc.2011.383","article-title":"BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients","volume":"105","author":"Kote-Jarai","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2017.06.002_bib1815","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/bjc.2012.146","article-title":"Germline BRCA1 mutations increase prostate cancer risk","volume":"106","author":"Leongamornlert","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2017.06.002_bib1820","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1038\/bjc.2014.30","article-title":"Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease","volume":"110","author":"Leongamornlert","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2017.06.002_bib1825","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/sj.bjc.6604453","article-title":"Rapid progression of prostate cancer in men with a BRCA2 mutation","volume":"99","author":"Narod","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2017.06.002_bib1830","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/jnci\/djm005","article-title":"Prostate cancer progression and survival in BRCA2 mutation carriers","volume":"99","author":"Tryggvadottir","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2017.06.002_bib1835","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","article-title":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer","volume":"31","author":"Castro","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1840","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.eururo.2014.10.022","article-title":"Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer","volume":"68","author":"Castro","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1845","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2017.06.002_bib1850","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.eururo.2017.02.023","article-title":"Treatment outcomes and tumor loss of heterozygosity in germline DNA repair-deficient prostate cancer","volume":"72","author":"Annala","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1855","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.eururo.2016.11.033","article-title":"Germline mutations in ATM and BRCA1\/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death","volume":"71","author":"Na","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1860","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.eururo.2014.01.003","article-title":"Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study","volume":"66","author":"Bancroft","year":"2014","journal-title":"Eur Urol"},{"issue":"Suppl 1","key":"10.1016\/j.eururo.2017.06.002_bib1865","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bju.12764","article-title":"Uro-oncology multidisciplinary meetings at an Australian tertiary referral centre\u2013impact on clinical decision-making and implications for patient inclusion","volume":"114","author":"Rao","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2017.06.002_bib1870","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/pon.3095","article-title":"Intervening to improve psychological outcomes for men with prostate cancer","volume":"22","author":"Chambers","year":"2013","journal-title":"Psychooncology"},{"key":"10.1016\/j.eururo.2017.06.002_bib1875","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1200\/JCO.2016.68.8788","article-title":"Mindfulness-based cognitive therapy in advanced prostate cancer: a randomized controlled trial","volume":"35","author":"Chambers","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1880","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/pon.3726","article-title":"A randomised controlled trial of a couples-based sexuality intervention for men with localised prostate cancer and their female partners","volume":"24","author":"Chambers","year":"2015","journal-title":"Psychooncology"},{"key":"10.1016\/j.eururo.2017.06.002_bib1885","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jsxm.2015.12.026","article-title":"Health-related quality of life, psychological distress, and sexual changes following prostate cancer: a comparison of gay and bisexual men with heterosexual men","volume":"13","author":"Ussher","year":"2016","journal-title":"J Sex Med"},{"key":"10.1016\/j.eururo.2017.06.002_bib1890","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.eururo.2015.12.032","article-title":"Physical activity and survival after prostate cancer","volume":"70","author":"Friedenreich","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1895","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1249\/01.mss.0000233803.48691.8b","article-title":"Resistance training and reduction of treatment side effects in prostate cancer patients","volume":"38","author":"Galvao","year":"2006","journal-title":"Med Sci Sports Exerc"},{"key":"10.1016\/j.eururo.2017.06.002_bib1900","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.eururo.2013.09.041","article-title":"A multicentre year-long randomised controlled trial of exercise training targeting physical functioning in men with prostate cancer previously treated with androgen suppression and radiation from TROG 03.04 RADAR","volume":"65","author":"Galvao","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1905","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.eururo.2016.12.025","article-title":"Management of prostate cancer in elderly patients: recommendations of a Task Force of the International Society of Geriatric Oncology","volume":"72","author":"Droz","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1910","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1038\/bjc.2015.120","article-title":"The impact of comprehensive geriatric assessment interventions on tolerance to chemotherapy in older people","volume":"112","author":"Kalsi","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2017.06.002_bib1915","first-page":"1518","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer","volume":"104","author":"Keating","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2017.06.002_bib1920","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jnci\/djp404","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer","volume":"102","author":"Keating","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2017.06.002_bib1925","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"Keating","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1930","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2008.20.0923","article-title":"Impact of androgen deprivation therapy on cardiovascular disease and diabetes","volume":"27","author":"Alibhai","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1935","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/jcem.87.2.8299","article-title":"Changes in body composition during androgen deprivation therapy for prostate cancer","volume":"87","author":"Smith","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eururo.2017.06.002_bib1940","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1210\/jc.2005-2507","article-title":"Insulin sensitivity during combined androgen blockade for prostate cancer","volume":"91","author":"Smith","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eururo.2017.06.002_bib1945","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1200\/JCO.2015.63.6266","article-title":"Androgen deprivation therapy and future Alzheimer's disease risk","volume":"34","author":"Nead","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1950","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/jamaoncol.2016.3662","article-title":"Association between androgen deprivation therapy and risk of dementia","volume":"3","author":"Nead","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1955","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1200\/JCO.2016.69.6203","article-title":"Androgen deprivation therapy and the risk of dementia in patients with prostate cancer","volume":"35","author":"Khosrow-Khavar","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.06.002_bib1960","doi-asserted-by":"crossref","first-page":"5030","DOI":"10.1200\/JCO.2010.30.8742","article-title":"Impact of androgen-deprivation therapy on cognitive function in men with nonmetastatic prostate cancer","volume":"28","author":"Alibhai","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283817304979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283817304979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T21:38:55Z","timestamp":1602365935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283817304979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":196,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0302283817304979"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2017.06.002","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2017.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 European Association of Urology. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}